In a randomized controlled study of BCG in the treatment of stage Ib and II malignant melanoma, both the disease-free survival rate and the survival rate in the BCG treated group were significantly higher than those in the control group. The survival rate in the stage Ib patients of the BCG-treated group are significantly higher than the control group. The survival rates in patients aged less than 60 were significantly higher in the BCG treated group than in the control group. The survival rates in male patients were significantly higher than in the control group.
Introduction
In order to improve the efficacy of treatment of malignant melanoma, many domestic and overseas investigators are attempting therapeutic methods in which chemotherapy and / or immunotherapy are concomitantly administered as adjuvant therapy to curative surgery. In Japan, DAV (DTIC +ACNU + VCR) therapy and PAV (PEP + ACNU + VCR) therapy are mainly employed as chemotherapy, while BCG, bestatin, forfenicinol, picibanil and Krestin are mainly employed for immunotherapy. Regarding bestatin and forfenicinol, randomized controlled studies were conducted, and in both studies the concomitant immunochemotherapy group (i. e., curative operation + immunotherapy + chemotherapy)
achieved better results than the concomitant chemotherapy group (i. e., curative operation+chemotherapy).
We have already reported the results obtained with bestatin and forfenicinol. Thus, in 
Results
In each of the three groups, the WBC count tended to be slightly increased. The lymphocyte count tended to be slightly increased in the 40 and 80 mg administration groups, while it showed no change in the 100 mg administration group. PPD remained unchanged in the 40 mg administration group, while it tended to be slightly increased in the 80 and 100 mg administration groups.
Flu-like symptoms, anorexia, abdominal discomfort, headache, fatigue, etc., were seen as side effects. The flu-like symptoms were severe in one case, and the administration of BCG was thus discontinued. In the other cases, the side effects were mild, and BCG administration was able to be continued.
Change in Lymphocyte Subsets Due to BCG Oral Administration

Materials and Methods
Thirty-one cases of skin cancer were divided into 3 groups consisting of 40-, 80-and 100 mg administration groups. The changes in lymphocyte subsets were investigated using monoclonal antibodies. Blood was collected before the initiation of administration and on the 7th day after administration in the 2nd week, and the values of the lymphocyte subsets were compared.
Results
There was a fairly clear tendency for the values of OKT-3 and the OKT-4 / OKT-8 ratio in the 80 mg administration group to approach the normal range ( Fig. 1) . In each administration group, the values of Leu-7 and ADCC activity tended to approach the normal range, and this tendency was especially striking in the 80 mg administration group
On the basis of the above-described data, the optimum dose of BCG was surmised to be about 80 mg.
Enteric BCG capsules have been produced by Japan BCG manufacturing Co. since 1978.
Their capsules are highly rated internationally since, compared to other BCG strains, their BCG strain (1) This study is still in progress. Fig. 3 shows the protocol for this study. There was practically no difference in either sex or the clinical stage between the two groups. Unlike the malignant melanoma encountered in Europe and America, it is characteristic of this malignancy in Japan that the primary lesion is frequently located in the sole. Also in this study, malignant melanoma of the sole has been found in 21. 4% more of the patients.
There was practically no difference in the frequency of location of the primary lesion between the BCG-treated and the control group.
Histologic typing of the patients has shown that NM (nodular melanoma) is the most frequent type, followed by ALM (acral lentiginous melanoma) together accounting for 84.
5% of the patients. SSM and LMM then follow. The frequency pattern of histologic type is obviously different from that in Europe and America.
Breslow's thickness has been found to be less than 3mm in 44 patients and 3mm or more in 51. There is practically no diffrence in this factor between the 2 groups ( Table 2 ).
Prognosis
We investigated the disease-free rate and survival rate of patients by Kaplan-Meier's method. The data were analyzed for statistically significant difference between the BCGtreated and the control group by generalized Wilcoxon's methods.
The disease-free rate begins to decrease after 4 months following the operation in the control group, and persists at about 20-30% lower than in the BCG-treated group. In other words, the disease-free rate in the BCG-treated group is significantly higher than that in the control group (Fig. 4) .
The survival rate decreases gradually from 9 months after the operation in the control group, and the difference in the rate between the BCG-treated and the control group tends to become greater after 38 months. In other words, the survival rate in the BCG-treated group is about 30% higher than that in the control group. The 5-year survival rate is 87. 4% for the BCG-treated group and 53. 2% for the control group (Fig. 5) .
The patients in both groups were then stratified to stage Ib and stage II. Both the disease -free interval rate and the survival rate in the stage Ib patients of the BCG-treated group are significantly higher than those in the control group (Fig. 6, 1 ) . The same rates in the stage II patients of the BCG-treated group are also higher than those in the control group. However, the disease free rate and the survival rate of BCG-treated group is not significantly higher than that in the control group.
The findings have led to the conclusion that in patients with stage Ib and II malignant melanoma, BCG prevents the recurrence and metastasis of the malignancy to a certain extent, and consequently prolongs the survival period especially in the stage Ib.
Prognosis by Age
The survival rate in patients more than 61 years of age are slightly higher in the BCG -treated group than in the control group. However, this difference is not of statistical significance. The survival rate in patients aged less than 60 years are far higher in the BCG -treated group than in the control group, there being a statistically significant difference between the 2 groups. The 5-year survial rate is 90. 8% for the BCG -treated group and 50. the control group. The 5-year survival rate is 96. 2% for the BCG-treated group and 67. 9% for the control group. The same rate in male patients is far higher in the BCG-treated group than in the control group, there being a statistically significant difference between the 2 groups. The 5-year survival rate is 78. 7% for the BCG-treated group and 41. 9% for the control group (78, 7 %) (Fig. 9) .
Side effects
From the total of 55 patients treated with BCG in this clinical trial, some sort of adverse reaction occurred in 3 patients (5. 5%). These adverse reactions consisted of digestive tract symptoms in 3 cases, i. e., nausea, diarrhea and abdominal discomfort in each patient, 
